Tepezza vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Tepezza | US Miebo | |
|---|---|---|
| Generic name | teprotumumab | perfluorohexyloctane |
| Drug class | IGF-1R Inhibitor (Biologic) | Semifluorinated Alkane (Eye Drop) |
| Treats | Thyroid eye disease | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Amgen | Bausch + Lomb |
| Year approved | 2020 | 2023 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Muscle spasms, Nausea, Hair loss, Hearing problems | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Tepezza or Miebo better?
Neither is universally "better." Tepezza (teprotumumab) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tepezza and Miebo?
Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tepezza has the larger estimated TV advertising budget of the two.